Status | In progress |
Technology type | Medicine |
Decision | Selected |
Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
Process | STA Standard |
ID number | 3932 |
Project Team
Project lead | Vonda Murray |
Email enquiries
- If you have any queries please email tateam3@nice.org.uk
External Assessment Group | Kleijnen Systematic Reviews Ltd |
Stakeholders
Companies sponsors | Merck Sharp & Dohme (belzutifan) |
Others | Department of Health and Social Care* |
Welsh Government | |
Patient carer groups | VHL UK/Ireland |
UK Kidney Association | |
Action Kidney Cancer | |
Professional groups | Association of Cancer Physicians |
Royal College of Physicians | |
Assessment group | Eusa Pharma UK (tivozanib) (confidentiality agreement signed, participating) |
Ipsen (cabozantinib) (confidentiality agreement signed, participating) | |
Accord Healthcare (everolimus) (confidentiality agreement not signed, not participating) | |
Bristol-Myers Squibb Pharmaceuticals (ipilimumab, nivolumab) (confidentiality agreement not signed, not participating) | |
Dr Reddy's Laboratories (everolimus) (confidentiality agreement not signed, not participating) | |
Eisai (lenvatinib) (confidentiality agreement not signed, not participating) | |
Merck (avelumab) (confidentiality agreement not signed, not participating) | |
Merck Sharp & Dohme (pembrolizumab) (confidentiality agreement not signed, not participating) | |
Novartis (everolimus, pazopanib) (confidentiality agreement not signed, not participating) | |
Pfizer (axitinib, sunitinib) (confidentiality agreement not signed, not participating) | |
Associated public health groups | None |
Evidence review group | Kleijnen Systematic Reviews |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
NHS England | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | National Institute for Health Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
29 November 2023 - 10 January 2024 | Draft guidance |
08 November 2023 | Committee meeting: 1 |
07 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
07 September 2023 | Topic selection |
07 September 2023 | In progress |
23 August 2023 | The topic routing was re-considered by the Topic Selection Oversight Panel (TSOP) in June 2023. The panel concluded that the topic should remain routed to the Technology Appraisal (TA) work programme. Please see project documents for further details. |
13 January 2023 | Invitation to participate |
23 November 2022 - 14 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
13 December 2022 | Topic selection |
29 November 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]. Following communications with the company the timelines for this appraisal have been revised. The appraisal is now anticipated to begin during early January 2023 when we will write to you about how you can get involved. |
29 December 2021 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early July 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
10 June 2021 - 08 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
26 May 2021 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
23 November 2020 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual